Search MGTX
MeiraGTx Holdings plc
Nasdaq · CIK 1735438
Last close10.79
Daily change+0.13 (1.22%)
10 Years gain-28.07%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
MGTX · STANDARD
SIC 2836 · Biological Products, (No Diagnostic Substances) · Fiscal year end 1231
Fundamental
80.8Momentum
n/aAcceleration
n/aConfidence
81.0Annual Revenue7
Quarterly Revenue23
Annual CFO9
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth25.0 / 25
Quality17.0 / 25
Capital Efficiency20.0 / 20
Balance Sheet12.5 / 15
Shareholder Economics2.4 / 10
Forward Indicators0.0 / 5
Signals
Net debt reductionNet debt declined versus the comparison period.
Warnings
Heavy share dilution · HIGHDiluted share count increased 18.6923%.
Key Metrics
Revenue Growth TTM2,258.51%OK
Revenue CAGR 3Y72.27%OK
Gross Margin100%OK
Operating Margin34.61%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC454.61%OK
Incremental Operating Margin 3Y70.04%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y18.69%OK
SBC / Revenue5.85%OK
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $81.39M | $81.39M | -$105.97M | -$46.36M | -$50.19M | 100% | -130.2% | -61.66% | n/a | 80.43M |
| 2025 FY Dec 31, 2024 | $33.28M | $33.28M | -$164.21M | -$104.50M | -$109.45M | 100% | -493.44% | -328.89% | n/a | 69.82M |
| 2024 FY Dec 31, 2023 | $14.02M | $14.02M | -$137.06M | -$105.37M | -$125.54M | 100% | -977.82% | -895.62% | -1,999.04% | 56.49M |
| 2023 FY Dec 31, 2022 | n/a | $15.92M | -$116.36M | -$73.10M | -$118.06M | n/a | n/a | n/a | n/a | 45.18M |
| 2021 FY Dec 31, 2022 | $15.92M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $325.83M | sum latest 4 fiscal quarters Revenue | OK | 0001104659-26-095504, 0001104659-25-110898 |
| Revenue Growth TTM | 2,258.51% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001104659-26-095504, 0001104659-25-110898 |
| Revenue CAGR 3Y | 72.27% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001104659-26-036494 |
| Revenue CAGR 5Y | 39.22% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001104659-26-036494 |
| Gross Profit CAGR 3Y | n/a | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | INSUFFICIENT_HISTORY | 0001104659-26-036494 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001104659-26-095504, 0001104659-25-110898 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 100% | Gross Profit / Revenue | OK | 0001104659-26-095504, 0001104659-25-110898 |
| Operating Margin | 34.61% | Operating Income / Revenue | OK | 0001104659-26-095504, 0001104659-25-110898 |
| ROIC | 454.61% | NOPAT / Average Invested Capital | OK | 0001104659-26-095504, 0001104659-25-110898 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001104659-26-095504 |
| Interest Coverage | 9.05x | Operating Income / abs(Interest Expense) | OK | derived |
| Current Ratio | 3.76x | Current Assets / Current Liabilities | OK | derived |
| SBC / Revenue | 5.85% | SBC / Revenue | OK | 0001104659-26-095504, 0001104659-26-060739 |